This blog entry has abbreviated/summarized these presentations. Though not intentional, some important material is likely to have been omitted; in addition, transcription errors are possible as well.
William Balistreri Prize: Katja Kovaic et al. Neurostimulation for functional abdominal pain disorders in children –a randomized, double-blind, sham-controlled trial. This study enrolled 104 patients. Lancet Gastroenterol Hepatol 2017; 2: 727-37.
Fellow Research Award: Symptoms Underestimate Endoscopic Activity in PSC-IBD. Amanda Ricciuto et al. Hospital for Sick Children.
- In patients with IBD-PSC, clinical remission based on clinical symptoms is not reliable indicator of histologic remission.
- Patients with PSC-IBD are more likely to have active endoscopic disease even when in “clinical remission”
- Calprotectin levels (not PUCAIs) are helpful in confirming clinical remission. A calprotectin <93 mcg/g was optimal level in determining clinical remission
- Better control of disease could improve clinical outcomes (eg. colon cancer, liver progression)
Keynote Address: Organoids: Current and future promise for changing treatment of gastrointestinal and liver disorders. James Wells Cincinnati Children’s Hospital Medical Center.
This was a terrific lecture.
- Example of use of pluripotent stem cell usage: Diabetes. Phase 1 study has been started.
- Organoids are in essence miniature versions of organs in a dish and with complex combination of cell types.
- Organoids allow easier testing on these tissues for treatment and diagnosis of diseases
- Organoids will allow for personalized testing of medications. Some patients will respond differently. This technology could be used to grow a specific organoid for a specific person and determine response on the organoid before giving to the patient.
- Can engraft organoids into mice which can provide blood supply and allow larger organoids.
- Clinical projects for organoids: Hirschsprung’s, H pylori, Clostridium difficile, Short bowel syndrome, Fatty liver disease